Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229722 · ClinicalTrials.gov registry record · NA
ARemind: A Personalized System to Remind for Adherence
A NA study of Medication Adherence, sponsored by Dimagi.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01229722 is a NA study of Medication Adherence that has completed, run by Dimagi. The registered enrollment target is 70 participants, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01229722, a NA study of Medication Adherence, has completed, sponsored by Dimagi.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The main aim of this phase II proposal is to continue and complete development of a cellular phone-based system that assists patients with their medication adherence. Adherence reports will be developed with feedback from patients and providers. Software for patients to report their four day recall adherence through text messaging or short message service (SMS) or interactive voice response (IVR) will be built. An initial qualitative study will evaluate the adherence reports, 4-day adherence recalls, and inform the development of content for reminder text messages that could be resistant to user fatigue. A redesigned system will be tested through a 3-week longitudinal study of 15 patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). An intervention module will have an analytics engine to track adherence levels and personalize delivery of reminder messages. A clinic appointment module will perform patient appointment reminders. The final system with these modules will be tested through a 24-week efficacy study. A total of 115 patients and providers will be involved in the three user studies.
Conditions Studied
Interventions
- DEVICE Beeper
- DEVICE ARemind
Study Locations (1)
Massachusetts
- Center for HIV/AIDS Care and Research, Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01229722
The ClinicalTrials.gov registry entry for NCT01229722 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (96% lower). The listed sponsor is Dimagi, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medication Adherence appearing as the primary indexed condition, and to 2 interventions - of which Beeper is the first listed.
NCT01229722 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01229722 about?
NCT01229722 is a clinical study titled "ARemind: A Personalized System to Remind for Adherence". The main aim of this phase II proposal is to continue and complete development of a cellular phone-based system that assists patients with their medication adherence. Adherence reports will be developed with feedback from patients and providers. Software for patients to report their four day recall ...
What is the current status of trial NCT01229722?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2011-10. Estimated completion is 2013-01.
What conditions does trial NCT01229722 study?
This clinical trial studies the following conditions: Medication Adherence.
What interventions are being tested in trial NCT01229722?
The interventions under investigation include: Beeper (DEVICE), ARemind (DEVICE).
Who is sponsoring clinical trial NCT01229722?
This trial is sponsored by Dimagi, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01229722 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Medication Adherence Program
RECRUITING · NA
-
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
RECRUITING · NA
-
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
RECRUITING · NA
-
Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.